Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 0.9335 |
|---|---|
| High | 0.9335 |
| Low | 0.9335 |
| Bid | 0.9335 |
| Offer | 0.985 |
| Previous close | 0.965 |
| Average volume | 0.00 |
|---|---|
| Shares outstanding | 31.20m |
| Free float | 30.46m |
| P/E (TTM) | -- |
| Market cap | 35.56m USD |
| EPS (TTM) | -1.11 USD |
Data delayed at least 15 minutes, as of Feb 11 2026 08:32 GMT.
More ▼
Press releases
- Actinium Pharmaceuticals Presents New Preclinical Data Demonstrating Potent Anti-Tumor Activity of ATNM-400 Across Multiple Breast Cancer Subtypes Including Hormone Receptor-Positive, Triple-Negative, and Tamoxifen- and HER2 Therapy-Resistant Breast Cancer Models at SABCS 2025
- Actinium Pharmaceuticals Announces ATNM-400 Data Demonstrating Potent Efficacy in Triple-Negative Breast Cancer and Ability to Overcome Endocrine and HER2-Targeted Therapy Resistance Being Presented at the San Antonio Breast Cancer Symposium
